2 Institute of Medical Biochemistry and 3 Swegene Proteomics Center, Göteborg University, Box 440, SE 405 30, Sweden; and 4 Glycoscience Research Centre, Auckland University of Technology, Private Bag 92006, Auckland 1020, New Zealand, and Kiwi Ingenuity Limited, P.O. Box 39373, Howick, New Zealand
Received on March 4, 2003; revised on August 31, 2003; accepted on September 3, 2003
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Key words: ABO / glycosyltransferase / histo-blood group antigen / Lewis / secretor
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
These studies clearly established the complex interactions of the secretor, Lewis, and A/B glycosyltransferases in determining the glycoconjugate profile of individuals. In particular they established that the amount and type of histo-blood grouprelated glycotopes was highly dependent on the relative expression of the specific glycosyltransferases. Of note was the observation that absence of some glycosyltransferase combinations resulted in increased quantities of elongated/branched glycolipids (Henry et al., 1994, 1997
). Although these studies established the presence of extended molecules, at the time they were unable to be fully structurally resolved mainly due to limitations of the technology and the relatively low quantity of sample available.
The blood group systems that affect blood group expression in the human GI tract include ABO, Lewis (FUT3), and secretor (FUT2) (as reviewed in Oriol, 1995). The various combinations of these different glycosyltransferases determine the range of glycoconjugate profiles expressed (Oriol, 1995
). The rarest profile (<1% of Caucasians) belongs to the group O Le(a-b-) nonsecretor who lacks functional glycosyltransferases for the ABO, Lewis, and secretor systems and thus represents a "null" blood group phenotype in the GI tract.
In the healthy GI tract, as with all other tissues of epithelial origin, type 1 (Galß3GlcNAc-R)based blood group glycotopes dominate. There is significant data reporting the presence of type 1based glycolipids with short chains bearing blood group glycotopes, in particular; type 1 precursor (Lec), type 1 H (Led), Lea, Leb, type 1 A, type 1 B, ALeb, and BLeb. In contrast, data on type 1based extended glycosphingolipids of intestinal origin is scarce. To date only six type 1based branched glycosphingolipid structures, all from rat small intestine, have been characterized by 1H nuclear magnetic resonance (NMR) (Bouhours et al., 1992; Breimer et al., 1982
; Hansson, 1983
).
In the absence of definitive NMR data of extended intestinal blood grouprelated glycolipids, reanalysis of the previously determined rat structures with type 1 inner core structures was necessary for unambiguous structural resolution. With the exception of the fucose residues, the two rat blood group Hactive decaglycosylceramides (Breimer et al., 1982) most closely resembled the potential branched structures present in our human sample. They were thus reanalyzed in identical solvents and temperatures for comparative purposes.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
Structural analysis of sample E24-5
Mass spectrometry (MS) analysis indicated that fraction E24-5 contained glycolipid components having four to eight sugars (results not shown), and exhibiting a profile similar to the lower m/z components (i.e., m/z 11002000) shown in Figure 1 for the later eluting fraction E24-6. These short glycolipids are also identified completely or inferred from partial assignments of the anomeric region in the NMR spectrum. The dominating structure in E24-5 is represented by Lec-4 (Table II, 1), which is estimated to be approximately 75% of the E24-5 sample. Also clearly evident are Fuc3 and Fuc
4 signals, representing Lex and Lea glycotopes, respectively. The structures carrying these glycotopes are mainly present as Lea-5 and Lex-5 (Table II, 5 and 6 respectively). However, the presence of a small amount of Lex-7 (internal glycotope; Levery et al., 1986
), repetitive Lex-8 (Hakomori et al., 1984
) and repetitive Lea-8 (Stroud et al., 1991
) may be inferred from the shifts of the Galß3/4 residues of the internally located glycotopes. Additionally, a small amount of the type 1 H-5 glycolipid (Table II, 3) is seen, as well as a barely visible Fuc
2 signal attributable to Leb-6 (Blaszczyk-Thurin et al., 1987
). The presence of Lea-5 and Leb-6 is compatible with earlier immunochemical findings of this Le(a-b-) nonsecretor individual (Henry et al., 1994
, 1997
).
|
|
|
Heptaosylceramides
MALDI m/z peaks correlating with monofucosylated heptaosylceramides were found over the range of m/z 1777 to m/z 1907, representing a variety of ceramides (Figure 1, Table III). Major ions were analyzed by ESI-MS/MS. The collision-induced dissociation (CID) spectrum of the m/z 900.0 doubly charged molecular sodium adduct [M + 2Na]2+ is shown in Figure 2. The spectrum correlates with two different Hex4HexNAc2Fuc1 structures, both having d18:1,h16:0 ceramide tails.
|
Octaosylceramides
MALDI m/z peaks, suggestive of a difucosylated octaosylceramide with a d18:1,h16:0 ceramide, were found at m/z 1923.3 (Figure 1, Table III). Other evidence for this structure with different ceramides was inconclusive. This structure was analyzed by ESI-MS/MS (Figure 3). The CID spectrum of the m/z 973.0 doubly charged molecular sodium adduct [M + 2Na]2+ correlates with a Hex4HexNAc2Fuc2 structure having a d18:1,h16:0 ceramide tail. This spectrum shows expected B- and Y-ions as indicated in the inset schematic diagram (Figure 3). CID of the m/z 973.0 [M + 2Na]2+ parent ion produced peaks at m/z 1777.0 [M - F]+, m/z 1630.9 [M - 2F]+, m/z 900.0 [M - F]2+, and m/z 826.9 [M - 2F]2+, showing the presence of two fucoses. Overall the ESI-MS/MS fragmentation patterns were strongly supportive of the Hex4HexNAc2Fuc2 structure shown in the inset of Figure 3.
|
|
|
|
|
Anomeric configurations remaining to be established are those of the two different core tetrasaccharides, that is, whether they belong to the lacto (type 1) or neolacto series (type 2). Starting with the minor component (decaosylceramide), the doublet of the core GlcNAcß3 is poorly visible in the 1D spectrum and is only seen as a shoulder on the high-field side of the Fuc3 H5 resonance at 4.66 ppm. However, in the COSY spectrum (Figure 7, 3:III) the positions of the H1 and H2 resonances at 4.64 ppm and 3.35 ppm, respectively, are clearly revealed and identifies this residue as a type 2 GlcNAcß3. Both the H1 and H2 resonances are shifted somewhat to a higher field due to the influence of the Fuc
3 residues of the Lex branches. The H1 resonance of the core GlcNAcß3 of the major component (nonaosylceramide), is found at 4.76 ppm (Table I, 4:III), a value that is consistent with a type 1 GlcNAcß3 residue equivalent to the rat H-10 type 1 structures described (Table I, 1:III and 4:III). This is also corroborated later by the identification of a core Galß3 residue.
The H1 resonance originating from the branching Galß4 of the minor component (decaosylceramide) should be expected around 4.29 ppm, and the Galß4 residue closest to the glucose of either component is expected in the neighborhood of 4.26 ppm (e.g., Hanfland et al., 1984). From the COSY spectrum (Figure 7, 3:IV), H1 and H2 resonances at 4.27 ppm and 3.43 ppm (Table I, 3:IV) respectively, are found. These values correspond closely to those expected except for the H1 resonance of the branching Galß4, which is somewhat shifted to a higher field due to the Fuc
3 residues of the Lex branches. Two of the three remaining H1 resonances at 4.20 ppm (H2 at 3.02 ppm) and 4.21 ppm (H2 at 3.00 ppm) are assigned to Glcß1 bound to different ceramides (Levery et al., 1986
), whereas the third H1 resonance, also at 4.21 ppm, in analogy with rat H-10 is assigned to the branching Galß3 of the major component (nonaosylceramide) because its H2 resonance was found at 3.41 ppm.
To summarize, the following two structures can be deduced from the combined analysis of the MS and NMR data presented: Galß4(Fuc3)GlcNAcß3(Galß4[Fuc
3]GlcNAcß6)Galß4GlcNAcß3Galß4Glcß1Cer and Galß3GlcNAcß3(Galß4[Fuc
3]GlcNAcß6)Galß3GlcNAcß3Galß4Glcß1Cer.
The decaosylceramide represents a novel structure, whereas the nonaosylceramide is identical to the structure isolated from blood group O Le(a-b-) plasma and characterized by MS and gas chromatographyMS but not by NMR (Hanfland et al., 1986).
As can be seen in the 1D spectrum of E24-6 (Figure 6) there are also three very minor contributions (23% each) stemming from compound(s) having a type 1 H determinant located on a 3-linked branch (Fuc2 H1 resonance at 4.98 ppm) and/or a 6-linked branch (Fuc
2 H1 resonance at 4.96 ppm). The presence of a Galß3 H1 resonance at 4.43 ppm, typical of type 1 H determinants, is also evident (see rat H-10 structures in Table I). The identity of the third component seen at 4.92 ppm is unclear.
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Published data on the structures present in Lewis-negative, secretor-negative individuals is rare. Two previous reports, one studying pooled plasma (Hanfland et al., 1986) and the other small intestine (Henry et al., 1997
), have concluded that lactotetraosylceramide is the dominating blood grouprelated glycolipid together with fucosylated extended branched structures. Other fucosylated structures are also present but at relatively low levels. Using more advanced techniques, we were able to revisit the structural analysis of small intestinal glycolipids from a group O Le(a-b-) nonsecretor individual (Henry et al., 1997
). In addition to the human intestinal glycolipids, type 1 inner-core branched glycolipids previously isolated from rat small intestine were reanalyzed. Although the rat structures were fucosylated, their NMR resonances were important to establish unambiguously the nature of the inner core structure of the human sample. Although neither of the rat molecules were present or expected in this human group O Le(a-b-) secretor negative sample, similar or identical structures could be predicted in group O Le(a-b-) secretor human intestine.
In the human sample we were able to show the presence of two extended branched structures, one a decaosylceramide bearing Lex on both branches and based on a type 2 internal chain. The other was a nonaosylceramide representing an extension of the dominating type 1 precursor (Lec-4) with a further unsubstituted 3-linked type 1 unit (Galß3GlcNAc) and a 6-linked fucosylated type 2 branch in the form of Lex. This molecule is identical to that previously isolated from pooled plasma of individuals of the same phenotype, although not unambiguously structurally resolved at that time (Hanfland et al., 1986).
Again and as previously noted, all the dominant structures larger than lactotetraosylceramide were fucosylated. Although some trace immunochemical evidence exists for Lea, type 1 H and Leb fucosylation (Henry et al., 1994; 1997
), almost all fucosylation observed was on type 2 chains and almost all type 2 chains were fucosylated. The virtual absence of type 1 fucosylation, as evidenced by lactotetraosylceramide and unsubstituted type 1 branches, clearly shows that the fucosyltransferase activity present during biosynthesis is restricted to type 2 chains. It would be expected that if these type 1 branches exist in Lewis/secretor positive individuals they would be appropriately fucosylated into H, Lea and Leb glycotopes.
It was clear from the studies on this sample that two types of glycolipid dominate; one being lactotetraosylceramide and the other extended structures. Subject to consideration and reservations about variables in the isolation procedures, which may be selective, we estimate that the relative ratios of lactotetraosylceramide, nonaosylceramide, decaosylceramide, and all other remaining glycolipids with more than four saccharides is approximately 50:30:10:10 by weight. It would be expected that losses that occur in the isolation procedure will predominantly affect the extended structures (Henry et al., 1997), and therefore they may be underestimated. Using polyglycosylceramide isolation procedures (Miller-Podraza et al., 1997
), there is no evidence that polyglycosylceramides are present in human small intestine, as they are in red cell membranes (Miller-Podraza, personal communication). Furthermore, it should be noted that this analysis relates to glycolipids; glycoprotein glycosylation was not studied and may show significant variance to glycolipids.
Using structural data generated from glycolipids isolated from this rare group O Le(a-b-) nonsecretor phenotype, we are now able to speculate on the biosynthesis of glycolipids in the human GI tract in the absence of ABO, Lewis, and secretor glycosyltransferases (Figure 8). Essentially two pathways operate, one for the type 1based molecules (Galß3GlcNAc-R) and the other for the type 2based (Galß4GlcNAc-R) molecules. In the type 2 pathway, ceramide dihexose (Galß4Glcß-cer) is converted into neolactotetraosylceramide, with a small amount converted into a range of linear structures bearing Lex internal and terminal glycotopes. However, most of the neolactotetraosylceramide appears to be then elongated with a type 2 (Galß4GlcNAc) unit, then branched, and both branches fucosylated. Although the order of fucosylation of the 3-linked branch is not known for certain (i.e., before or after branching), it is expected to occur after branching, as it is known that terminal and internal fucosylation, at least in rats, prevents branch formation (Leppänen et al., 1997).
|
Essentially in the type 1 pathway, ceramide dihexose (Galß4Glcß1Cer) is converted into lactotetraosylceramide, and again a small amount is converted into a range of linear structures, this time bearing Lea internal and terminal glycotopes. However, in contrast to the type 2 pathway, most of the tetraosylceramide appears to remain unmodified. All the same, a significant amount is elongated with a type 1 (Galß3GlcNAc) unit into a lactohexaosylceramide (Henry et al., 1997). There was no evidence for 3-linked type 2 extension of the inner core, which is in agreement with the extended molecules found in the rat. After extension into type 1 lactohexaosylceramide, the molecule is then branched (6-linked) with a type 2 unit, and this type 2 branch is always fucosylated. This fucosylation appears to be complete, as there was no evidence for unsubstituted 6-linked type 2 branches. For the extended linear structures, we have suggested that the pathway involves chain extension of Lea or Lex, rather than extension and then fucosylation. This is speculative and remains to be proven by enzymatic studies.
No core structures larger than the molecules reported here have been found in Lewis-positive human small intestine (unpublished data). Only substitutions of these cores by secretor, Lewis, and ABO glycosyltransferases to form a limited range of structures have been found. Therefore, unlike red cells, in which chain extension and branching dominate, glycolipids of the small intestine are restricted in size and structure. This process of extension appears to be restricted by both branching and fucosylation. The reason for this restriction in chain extension is unknown, but as each different glycoconjugate may represent a potential receptor to which microorganisms can specifically attach (Karlsson, 1986; Hooper and Gordon, 2001
), it is possible this limited range has developed as a result of biological tension. Only further understanding of the biosynthetic pathway, resulting in the formation of the various blood group glycoconjugates, will lead us to an understanding of their biological significance and the evolutionary pressures that drive carbohydrate blood group polymorphism.
![]() |
Materials and methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The new deacetylation step uses a methanol:water: chloroform mix (65:35:16 by volume) containing 0.2 M KOH, (100 ml/g lipid) instead of simply 0.2 M KOH in methanol, and is allowed to proceed overnight instead of 3 h as previously described (Karlsson, 1987). The reactants are then dialysed as a two-phase system against water. This new step successfully removed almost all unwanted O-acetylated residues (as determined by MS) of native glycolipids. Overall and with respect to the changes indicated, the entire glycolipid isolation procedure involved solvent extraction of total lipids with methanol and chloroform:methanol (2:1 by volume) at 70°C; mild alkaline degradation with KOH followed by dialysis to remove lipids with alkali labile ester linkages; silica chromatography fractionation with chloroform:methanol (99:1 by volume) to remove unwanted nonpolar lipids and chloroform:methanol (1:3 by volume), methanol and chloroform:methanol:water (40:40:12 by volume) to recover a crude glycolipid containing sample. This sample was then loaded onto a DEAE cellulose ion exchange column and unbound material including the nonacid glycolipids were removed with chloroform:methanol (2:1 by volume) and methanol.
This crude total nonacid lipid sample was acetylated and fractionated on an open silica column with the acetylated glycolipids recovered with the solvent chloroform:methanol (95:5 by volume). The acetylated glycolipids were deacetylated according to the original method but later redeacetylated by the method described here. The sample was then subjected to a DEAE cellulose ion-exchange column and a further silica column as described. The resultant total neutral glycolipids were then fractionated in an open silica column using the solvent system of chloroform:methanol: water (60:35:12 by volume) to recover the glycolipids as previously described (Henry et al., 1997). Two fractions for structural analysis were obtained; E24-5 containing predominantly shorter structures, and E24-6 containing extended structures.
MS
MALDI spectra were obtained on a TofSpec E (Micromass, Manchester, U.K.) equipped with a time lag focusing unit. All spectra were recorded in the reflectron mode, with an accelerating voltage of 20 kV. Half a microliter of matrix solution, 2,5-dihydroxybenzoic acid, 20 mg/ml (Aldrich, St. Louis, MO) dissolved in acetone, was deposited on the target and allowed to dry. One microliter of the sample solution was added to the matrix spot and the redissolved matrixsample mixture was then allowed to dry in air. An external calibration sample (ethylated polyfructanes) was loaded in parallel. The monoisotopic masses obtained (sodium adducts) were compared to theoretical glycosphingolipid masses using an in-house program.
ESI-MS/MS data were acquired on a Q-Tof (Micromass) hybrid quadrupole time-of-flight instrument using the nanospray source. Samples were dissolved in methanol containing 1% H2O. Doubly charged ions (sodium adducts) were chosen and subjected to MS/MS using argon as the collision gas and with the collision energy varied between 3080 V.
Spectra have been annotated with masses that correspond to monoisotopic peaks. Diagnostic fragments arise from fragmentation of the doubly charged parent ions. In this article we tried to make interpretation and annotation of the spectra as simple as possible for the nonspecialist to read. Because ESI-MS produces a lot of secondary ions by loss of branches, the nomenclature gets very complicated, especially with respect to annotation of figures. Consequently we use the Domon and Costello (1988) nomenclature only to indicate from which "end" of the molecule the primary ions originate.
The B series of ions, B-ions, represent the terminal saccharide fragments (less one hydrogen). The Y series correspond with those representing the ceramide containing fragment (plus one hydrogen). The ions are assigned a name according to the number of saccharides it contains, for instance, B3 are the three terminal saccharides. If a further bond is broken, for example loss of fucose, it is called B3-F, indicating the terminal trisaccharide which has lost fucose. Both the B and Y series also produce ions caused by the further loss of fucose. Singly and doubly charged molecular ions with one or two sodium adducts are also seen, [M + Na]+ and [M + 2Na]2+, respectively. Also, fragment ions can carry two charges and the state is designated 2+, for example, [M - F]2+. If not designated, it is singly charged. Other fragmentation ions (other than B and Y series) were often also present but have not been annotated or commented on.
Proton NMR spectroscopy
1H NMR spectra were acquired on Varian 500 and 600 MHz spectrometers at 30°C. Samples were dissolved in DMSO/D2O (98/2, by volume) after deuterium exchange. Two-dimensional double quantum-filtered COSY spectra were recorded by the standard pulse sequence (Marion and Wüthrich, 1983) using 32 scans per t1 increment in 2K* 256 point matrices.
![]() |
Acknowledgements |
---|
![]() |
Footnotes |
---|
![]() |
Abbreviations |
---|
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Blaszczyk-Thurin, M., Thurin, J., Hindsgaul, O., Karlsson, K.-A., Steplewski, Z., and Koprowski, H. (1987) Y and blood group B type 2 glycolipid antigens accumulate in a human gastric carcinoma cell line as detected by monoclonal antibody. J. Biol. Chem., 262, 372379.
Bouhours, D., Hansson, G.C., Ångström, J., Jovall, P.Å., and Bouhours, J.F. (1992) Two novel decaglycosylceramides with a blood group A-active tetrasaccharide repeat in the epithelial cells of the small intestine of inbred rats. J. Biol. Chem., 267, 1853318540.
Breimer, M.E. (1984) Tissue specificity of glycosphingolipids as expressed in pancreas and small intestine of blood group A and B human individuals. Arch. Biochem. Biophys., 228, 7185.[ISI][Medline]
Breimer, M.E., Falk, K., Hansson, G.C., and Karlsson, K. (1982) Structural identification of two ten-sugar branched chain glycosphingolipids of blood group H type present in epithelial cells of rat small intestine. J. Biol. Chem., 257, 5059.
Breimer, M.E., Karlsson, K.A., and Samuelsson, B.E. (1983) Chemical characterization of a blood group H type pentaglycosylceramide of human small intestine. Chem. Phys. Lipids, 33, 135144.[CrossRef][ISI][Medline]
Clausen, H., Levery, S.B., McKibbin, J.M., and Hakomori, S.-i. (1985) Blood group A determinants with mono- and difucosyl type 1 chain in human erythrocyte membranes. Biochemistry, 24, 35783586.[ISI][Medline]
Clausen, H., Levery, S.B., Kannagi, R., and Hakomori, S.-i. (1986) Novel blood group H glycolipid antigens exclusively expressed in blood group A and AB erythrocytes (type 3 chain H). I. Isolation and chemical characterization. J. Biol. Chem., 261, 13801387.
Dabrowski, J., Hanfland, P., Egge H., and Dabrowski, U. (1981) Immunochemistry of the Lewis-blood-group system: proton nuclear magnetic resonance study of plasmatic Lewis-blood-group-active glycosphingolipids and related substances. Arch. Biochem. Biophys., 210, 405411.[ISI][Medline]
Domon, B. and Costello, C.E. (1988) A systematic nomenclature for carbohydrate fragmentations in FAB-MS/MS spectra of glycoconjugates. Glycoconj. Ji, 5, 397409.
Falk, K.-E., Karlsson, K.-A., Leffler, H., and Samuelsson, B.E. (1979) Specific pattern of glycosphingolipids enriched in a mucosa scraping of human small intestine. FEBS Lett., 101, 273276.[CrossRef][ISI][Medline]
Finne, J., Breimer, M.E., Hansson, G.C., Karlsson, K.-A., Leffler, H., Vliegenthart, J.F., and van Halbeek, H. (1989) Novel polyfucosylated N-linked glycopeptides with blood group A, H, X, and Y determinants from human small intestinal epithelial cells. J. Biol. Chem., 264, 57205735.
Hakomori, S.-i., Nudelman, E., Levery, S.B., and Kannagi, R. (1984) Novel fucolipids accumulating in human adenocarcinoma. I. Glycolipids with di- or trifucosylated type 2 chain. J. Biol. Chem., 259, 46724680.
Hanfland, P., Kordowicz, M., Niermann, H., Egge, H., Dabrowski, U., Peter Katalinic, J., and Dabrowski, J. (1984) Purification and structures of branched blood-group-B-active glycosphingolipids from human erythrocyte membranes. Eur. J. Biochem., 145, 531542.[Abstract]
Hanfland, P., Kordowicz, M., Peter Katalinic, J., Pfannschmidt, G., Crawford, R.J., and Graham, H. A. (1986) Immunochemistry of the Lewis blood-group system: isolation and structures of Lewis-c active and related glycosphingolipids from the plasma of blood-group O Le(a-b-) nonsecretors. Arch. Biochem. Biophys., 246, 655672.[ISI][Medline]
Hansson, G.C. (1983) The structure of two blood group A-active glycosphingolipids with 12 sugars and a branched chain present in the epithelial cells of rat small intestine. J. Biol. Chem., 258, 96129615.
Henry, S., Jovall, P.-Å., Ghardashkhani, S., Elmgren, A., Martinsson, T., Larson, G., and Samuelsson, B. (1997) Structural and immunochemical identification of Lea, Leb, H type 1, and related glycolipids in small intestinal mucosa of a group O Le(a-b-) nonsecretor. Glycoconj. J., 14, 209223.[CrossRef][ISI][Medline]
Henry, S.M. (2001) Molecular diversity in the biosynthesis of GI tract glycoconjugates. A blood group related chart of microorganism receptors. Transfus. Clin. Biol., 8, 226230.[CrossRef][ISI][Medline]
Henry, S.M., Samuelsson, B.E., and Oriol, R. (1994) Immunochemical and immunohistological expression of Lewis histo-blood group antigens in small intestine including individuals of the Le(a+b+) and Le(a-b-) nonsecretor phenotypes. Glycoconj. J., 11, 600607.[ISI][Medline]
Holgersson, J., Strömberg N., and Breimer M.E. (1988) Glycolipids of human large intestine: difference in glycolipid expression related to anatomical localization, epithelial/non-epithelial tissue and the ABO, Le and Se phenotypes of the donors. Biochimie, 70, 15651574.[CrossRef][ISI][Medline]
Holmes, E.H. and Levery, S.B. (1989) Preparative in vitro generation of lacto-series type 1 chain glycolipids catalyzed by beta 13-galactosyltransferase from human colonic adenocarcinoma Colo 205 cells. Arch. Biochem. Biophys., 274, 1425.[ISI][Medline]
Hooper, L.V. and Gordon, J.I. (2001) Glycans as legislators of host-microbial interactions: spanning the spectrum from symbiosis to pathogenicity. Glycobiology, 11, 1R10R.
Karlsson, K.-A. (1986) Animal glycolipids as attachment sites for microbes. Chem. Phys. Lipids, 42, 153172.[CrossRef][ISI][Medline]
Karlsson, K.-A. (1987) Preparation of total nonacid glycolipids for overlay analysis of receptors for bacteria and viruses and for other studies. Methods Enzymol., 138, 212220.[ISI][Medline]
Lanne, B., Olsson, B.M., Jovall, P.-Å., Ångström, J., Linder, H., Marklund, B.I., Bergstrom, J., and Karlsson, K.-A. (1995) Glycoconjugate receptors for P-fimbriated Escherichia coli in the mouse. An animal model of urinary tract infection. J. Biol. Chem., 270, 90179025.
Leppänen, A., Niemelä, R., and Renkonen, O. (1997) Enzymatic midchain branching of polylactosamine backbones is restricted in a site-specific manner in 1,3-fucosylated chains. Biochemistry, 36, 1372913735.[CrossRef][ISI][Medline]
Levery, S.B., Nudelman, E.D., Andersen, N.H., and Hakomori, S.-i. (1986) 1H-n.m.r. analysis of glycolipids possessing mono- and multi-meric X and Y haptens: characterization of two novel extended Y structures from human adenocarcinoma. Carbohydr. Res., 151, 311328.[CrossRef][ISI][Medline]
Levery, S.B., Nudelman, E., Kannagi, R., Symington, F.W., Andersen, N.H., Clausen, H., Baldwin, M., and Hakomori, S.-i. (1988) 1H-n.m.r. analysis of type-2 chain lacto-gangliosides. Confirmation of structure of a novel cancer-associated fucoganglioside, -NeuAc-(2
6)-ß-D-Galp-(1
4)-ß-D-GlcpNAc-(1
3)-ß-D-Galp-(1
4)-[
-L-Fucp-(1
3)]-ß-D-GlcpNAc-(1
3)-ß-D-Galp-(1
4)-ß-D-Glcp-(1
1)-Cer (VI6NeuAcIII3FucnLc6Cer). Carbohydr. Res., 178, 121144.[CrossRef][ISI][Medline]
Marion, D. and Wüthrich, K. (1983) Application of phase sensitive two-dimensional correlated spectroscopy (COSY) for measurements of 1H-1H spin-spin coupling constants in proteins. Biochem. Biophys. Res. Commun., 113, 967974.[ISI][Medline]
Miller-Podraza, H., Stenhagen, G., Larsson, T., Andersson, C., and Karlsson, K.-A. (1997) Screening for the presence of polyglycosylceramides in various tissues: partial characterization of blood group-active complex glycosphingolipids of rabbit and dog small intestines. Glycoconj. J., 14, 231239.[CrossRef][ISI][Medline]
Oriol, R. (1995) ABO, Hh, Lewis and secretion. Serology, genetics and tissue distribution. In Cartron, J.P. and Rouger, P. (Eds.), Blood cell biochemistry, 6th ed. Plenum Press, New York, pp. 3773.
Stroud, M.R., Levery, S.B., Nudelman, E.D., Salyan, M.E.K., Towell, J.A., Roberts, C.E., Watanabe, M., and Hakomori, S.-i. (1991) Extended Type 1 chain glycosphingolipids: dimeric Lea (III4V4Fuc2Lc6) as human tumor-associated antigen. J. Biol. Chem., 266, 84398446.
Szulman, A.E. and Marcus, D.M. (1973) The histologic distribution of the blood group substances in man as disclosed by immunofluorescence. VI. The Lea and Leb antigens during fetal development. Lab. Invest., 28, 565574.[ISI][Medline]